nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCG2—Leflunomide—rheumatoid arthritis	0.0557	0.107	CbGbCtD
Ponatinib—ABCB11—Cyclosporine—rheumatoid arthritis	0.0548	0.106	CbGbCtD
Ponatinib—ABCB11—Dexamethasone—rheumatoid arthritis	0.0361	0.0696	CbGbCtD
Ponatinib—ABCG2—Sulfasalazine—rheumatoid arthritis	0.0344	0.0663	CbGbCtD
Ponatinib—ABCG2—Hydrocortisone—rheumatoid arthritis	0.0276	0.0532	CbGbCtD
Ponatinib—ABCG2—Cyclosporine—rheumatoid arthritis	0.0261	0.0503	CbGbCtD
Ponatinib—CYP3A5—Sulfasalazine—rheumatoid arthritis	0.0191	0.0367	CbGbCtD
Ponatinib—ABCG2—Dexamethasone—rheumatoid arthritis	0.0172	0.0331	CbGbCtD
Ponatinib—ABCB1—Methylprednisolone—rheumatoid arthritis	0.0164	0.0315	CbGbCtD
Ponatinib—CYP3A5—Hydrocortisone—rheumatoid arthritis	0.0153	0.0295	CbGbCtD
Ponatinib—CYP2C8—Hydrocortisone—rheumatoid arthritis	0.0147	0.0283	CbGbCtD
Ponatinib—CYP3A5—Cyclosporine—rheumatoid arthritis	0.0144	0.0278	CbGbCtD
Ponatinib—CYP2C8—Cyclosporine—rheumatoid arthritis	0.0139	0.0268	CbGbCtD
Ponatinib—ABCG2—Methotrexate—rheumatoid arthritis	0.0138	0.0266	CbGbCtD
Ponatinib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.0133	0.0256	CbGbCtD
Ponatinib—ABCB1—Betamethasone—rheumatoid arthritis	0.0106	0.0205	CbGbCtD
Ponatinib—ABCB1—Prednisolone—rheumatoid arthritis	0.0105	0.0202	CbGbCtD
Ponatinib—ABCB1—Hydrocortisone—rheumatoid arthritis	0.00995	0.0192	CbGbCtD
Ponatinib—ABCB1—Prednisone—rheumatoid arthritis	0.00991	0.0191	CbGbCtD
Ponatinib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.0098	0.0189	CbGbCtD
Ponatinib—CYP3A5—Dexamethasone—rheumatoid arthritis	0.00951	0.0183	CbGbCtD
Ponatinib—ABCB1—Cyclosporine—rheumatoid arthritis	0.0094	0.0181	CbGbCtD
Ponatinib—CYP2C8—Dexamethasone—rheumatoid arthritis	0.00914	0.0176	CbGbCtD
Ponatinib—CYP2D6—Cyclosporine—rheumatoid arthritis	0.00885	0.0171	CbGbCtD
Ponatinib—FGFR3—cartilage tissue—rheumatoid arthritis	0.00759	0.118	CbGeAlD
Ponatinib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.00743	0.0143	CbGbCtD
Ponatinib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00637	0.0123	CbGbCtD
Ponatinib—CYP3A4—Prednisolone—rheumatoid arthritis	0.00629	0.0121	CbGbCtD
Ponatinib—ABCB1—Dexamethasone—rheumatoid arthritis	0.00619	0.0119	CbGbCtD
Ponatinib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00596	0.0115	CbGbCtD
Ponatinib—CYP3A4—Prednisone—rheumatoid arthritis	0.00594	0.0115	CbGbCtD
Ponatinib—CYP2D6—Dexamethasone—rheumatoid arthritis	0.00583	0.0112	CbGbCtD
Ponatinib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.00563	0.0109	CbGbCtD
Ponatinib—ABCB1—Methotrexate—rheumatoid arthritis	0.00497	0.00959	CbGbCtD
Ponatinib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.00371	0.00715	CbGbCtD
Ponatinib—Imatinib—PIP4K2C—rheumatoid arthritis	0.00333	0.442	CrCbGaD
Ponatinib—FGFR4—connective tissue—rheumatoid arthritis	0.00277	0.0429	CbGeAlD
Ponatinib—FGFR2—exocrine gland—rheumatoid arthritis	0.0027	0.0418	CbGeAlD
Ponatinib—Nilotinib—MAPK8—rheumatoid arthritis	0.00238	0.315	CrCbGaD
Ponatinib—FGFR4—digestive system—rheumatoid arthritis	0.002	0.031	CbGeAlD
Ponatinib—LYN—connective tissue—rheumatoid arthritis	0.0019	0.0294	CbGeAlD
Ponatinib—FGFR3—connective tissue—rheumatoid arthritis	0.00189	0.0292	CbGeAlD
Ponatinib—KIT—exocrine gland—rheumatoid arthritis	0.00187	0.029	CbGeAlD
Ponatinib—BCR—parotid gland—rheumatoid arthritis	0.00186	0.0288	CbGeAlD
Ponatinib—BCR—saliva-secreting gland—rheumatoid arthritis	0.00178	0.0275	CbGeAlD
Ponatinib—Nilotinib—BLK—rheumatoid arthritis	0.00164	0.217	CrCbGaD
Ponatinib—FLT3—connective tissue—rheumatoid arthritis	0.00162	0.0251	CbGeAlD
Ponatinib—LYN—lymphoid tissue—rheumatoid arthritis	0.00139	0.0215	CbGeAlD
Ponatinib—FGFR2—saliva-secreting gland—rheumatoid arthritis	0.00134	0.0208	CbGeAlD
Ponatinib—RET—connective tissue—rheumatoid arthritis	0.0013	0.0202	CbGeAlD
Ponatinib—FGFR2—connective tissue—rheumatoid arthritis	0.00124	0.0191	CbGeAlD
Ponatinib—BCR—lymphoid tissue—rheumatoid arthritis	0.00119	0.0185	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—rheumatoid arthritis	0.00119	0.0184	CbGeAlD
Ponatinib—TEK—connective tissue—rheumatoid arthritis	0.00118	0.0184	CbGeAlD
Ponatinib—BCR—tendon—rheumatoid arthritis	0.00112	0.0174	CbGeAlD
Ponatinib—KDR—parotid gland—rheumatoid arthritis	0.0011	0.017	CbGeAlD
Ponatinib—PDGFRA—connective tissue—rheumatoid arthritis	0.00107	0.0166	CbGeAlD
Ponatinib—KDR—saliva-secreting gland—rheumatoid arthritis	0.00105	0.0163	CbGeAlD
Ponatinib—SRC—connective tissue—rheumatoid arthritis	0.00105	0.0163	CbGeAlD
Ponatinib—FGFR1—tendon—rheumatoid arthritis	0.000999	0.0155	CbGeAlD
Ponatinib—KIT—parotid gland—rheumatoid arthritis	0.000975	0.0151	CbGeAlD
Ponatinib—KDR—connective tissue—rheumatoid arthritis	0.000968	0.015	CbGeAlD
Ponatinib—RET—lymphoid tissue—rheumatoid arthritis	0.000951	0.0147	CbGeAlD
Ponatinib—RET—digestive system—rheumatoid arthritis	0.000939	0.0146	CbGeAlD
Ponatinib—KIT—saliva-secreting gland—rheumatoid arthritis	0.000934	0.0145	CbGeAlD
Ponatinib—ABCB11—digestive system—rheumatoid arthritis	0.000917	0.0142	CbGeAlD
Ponatinib—RET—tendon—rheumatoid arthritis	0.000894	0.0139	CbGeAlD
Ponatinib—FGFR2—digestive system—rheumatoid arthritis	0.000893	0.0138	CbGeAlD
Ponatinib—TEK—lymphoid tissue—rheumatoid arthritis	0.000866	0.0134	CbGeAlD
Ponatinib—KIT—connective tissue—rheumatoid arthritis	0.000858	0.0133	CbGeAlD
Ponatinib—ABL1—parotid gland—rheumatoid arthritis	0.000849	0.0132	CbGeAlD
Ponatinib—TEK—tendon—rheumatoid arthritis	0.000814	0.0126	CbGeAlD
Ponatinib—ABL1—saliva-secreting gland—rheumatoid arthritis	0.000813	0.0126	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—rheumatoid arthritis	0.000785	0.0122	CbGeAlD
Ponatinib—PDGFRA—digestive system—rheumatoid arthritis	0.000775	0.012	CbGeAlD
Ponatinib—SRC—lymphoid tissue—rheumatoid arthritis	0.00077	0.0119	CbGeAlD
Ponatinib—SRC—digestive system—rheumatoid arthritis	0.00076	0.0118	CbGeAlD
Ponatinib—ABL1—connective tissue—rheumatoid arthritis	0.000747	0.0116	CbGeAlD
Ponatinib—PDGFRA—tendon—rheumatoid arthritis	0.000738	0.0114	CbGeAlD
Ponatinib—KDR—lymphoid tissue—rheumatoid arthritis	0.000708	0.011	CbGeAlD
Ponatinib—KDR—digestive system—rheumatoid arthritis	0.000699	0.0108	CbGeAlD
Ponatinib—KDR—tendon—rheumatoid arthritis	0.000666	0.0103	CbGeAlD
Ponatinib—KIT—lymphoid tissue—rheumatoid arthritis	0.000627	0.00972	CbGeAlD
Ponatinib—KIT—digestive system—rheumatoid arthritis	0.00062	0.0096	CbGeAlD
Ponatinib—ABL1—lymphoid tissue—rheumatoid arthritis	0.000546	0.00846	CbGeAlD
Ponatinib—ABL1—digestive system—rheumatoid arthritis	0.00054	0.00836	CbGeAlD
Ponatinib—ABCG2—parotid gland—rheumatoid arthritis	0.000535	0.00829	CbGeAlD
Ponatinib—ABL1—tendon—rheumatoid arthritis	0.000513	0.00796	CbGeAlD
Ponatinib—ABCG2—saliva-secreting gland—rheumatoid arthritis	0.000513	0.00794	CbGeAlD
Ponatinib—CYP3A5—digestive system—rheumatoid arthritis	0.000316	0.00489	CbGeAlD
Ponatinib—CYP3A4—digestive system—rheumatoid arthritis	0.000237	0.00367	CbGeAlD
Ponatinib—CYP2D6—digestive system—rheumatoid arthritis	0.000233	0.00361	CbGeAlD
Ponatinib—Imatinib—ALB—rheumatoid arthritis	0.000195	0.0258	CrCbGaD
Ponatinib—ABCB1—lymphoid tissue—rheumatoid arthritis	0.00017	0.00263	CbGeAlD
Ponatinib—ABCB1—digestive system—rheumatoid arthritis	0.000168	0.0026	CbGeAlD
Ponatinib—Infection—Hydrocortisone—rheumatoid arthritis	0.000122	0.000758	CcSEcCtD
Ponatinib—Dyspepsia—Cyclosporine—rheumatoid arthritis	0.000121	0.000756	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisolone—rheumatoid arthritis	0.000121	0.000755	CcSEcCtD
Ponatinib—Myalgia—Triamcinolone—rheumatoid arthritis	0.00012	0.000749	CcSEcCtD
Ponatinib—Vomiting—Azathioprine—rheumatoid arthritis	0.00012	0.000749	CcSEcCtD
Ponatinib—Nervous system disorder—Hydrocortisone—rheumatoid arthritis	0.00012	0.000748	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—rheumatoid arthritis	0.00012	0.000748	CcSEcCtD
Ponatinib—Myalgia—Methylprednisolone—rheumatoid arthritis	0.00012	0.000748	CcSEcCtD
Ponatinib—Arthralgia—Methylprednisolone—rheumatoid arthritis	0.00012	0.000748	CcSEcCtD
Ponatinib—Eye disorder—Prednisone—rheumatoid arthritis	0.00012	0.000747	CcSEcCtD
Ponatinib—Decreased appetite—Cyclosporine—rheumatoid arthritis	0.00012	0.000746	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—rheumatoid arthritis	0.00012	0.000744	CcSEcCtD
Ponatinib—Infestation—Methotrexate—rheumatoid arthritis	0.00012	0.000744	CcSEcCtD
Ponatinib—Rash—Azathioprine—rheumatoid arthritis	0.000119	0.000743	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—rheumatoid arthritis	0.000119	0.000743	CcSEcCtD
Ponatinib—Dermatitis—Azathioprine—rheumatoid arthritis	0.000119	0.000742	CcSEcCtD
Ponatinib—Flushing—Prednisone—rheumatoid arthritis	0.000119	0.000742	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cyclosporine—rheumatoid arthritis	0.000119	0.000741	CcSEcCtD
Ponatinib—Skin disorder—Hydrocortisone—rheumatoid arthritis	0.000119	0.000741	CcSEcCtD
Ponatinib—Fatigue—Cyclosporine—rheumatoid arthritis	0.000119	0.00074	CcSEcCtD
Ponatinib—Headache—Azathioprine—rheumatoid arthritis	0.000119	0.000738	CcSEcCtD
Ponatinib—Hyperhidrosis—Hydrocortisone—rheumatoid arthritis	0.000119	0.000738	CcSEcCtD
Ponatinib—Dizziness—Leflunomide—rheumatoid arthritis	0.000118	0.000736	CcSEcCtD
Ponatinib—Constipation—Cyclosporine—rheumatoid arthritis	0.000118	0.000734	CcSEcCtD
Ponatinib—Pain—Cyclosporine—rheumatoid arthritis	0.000118	0.000734	CcSEcCtD
Ponatinib—Dry mouth—Triamcinolone—rheumatoid arthritis	0.000118	0.000733	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—rheumatoid arthritis	0.000117	0.000725	CcSEcCtD
Ponatinib—Angiopathy—Prednisone—rheumatoid arthritis	0.000117	0.000725	CcSEcCtD
Ponatinib—Oedema—Triamcinolone—rheumatoid arthritis	0.000115	0.000718	CcSEcCtD
Ponatinib—Arrhythmia—Prednisone—rheumatoid arthritis	0.000115	0.000714	CcSEcCtD
Ponatinib—Infection—Triamcinolone—rheumatoid arthritis	0.000115	0.000714	CcSEcCtD
Ponatinib—Infection—Methylprednisolone—rheumatoid arthritis	0.000114	0.000712	CcSEcCtD
Ponatinib—Vomiting—Leflunomide—rheumatoid arthritis	0.000114	0.000707	CcSEcCtD
Ponatinib—Insomnia—Prednisolone—rheumatoid arthritis	0.000114	0.000707	CcSEcCtD
Ponatinib—Alopecia—Prednisone—rheumatoid arthritis	0.000113	0.000706	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—rheumatoid arthritis	0.000113	0.000704	CcSEcCtD
Ponatinib—Nervous system disorder—Methylprednisolone—rheumatoid arthritis	0.000113	0.000703	CcSEcCtD
Ponatinib—Gastrointestinal pain—Cyclosporine—rheumatoid arthritis	0.000113	0.000702	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—rheumatoid arthritis	0.000113	0.000702	CcSEcCtD
Ponatinib—Paraesthesia—Prednisolone—rheumatoid arthritis	0.000113	0.000702	CcSEcCtD
Ponatinib—Rash—Leflunomide—rheumatoid arthritis	0.000113	0.000701	CcSEcCtD
Ponatinib—Dermatitis—Leflunomide—rheumatoid arthritis	0.000113	0.000701	CcSEcCtD
Ponatinib—Mental disorder—Prednisone—rheumatoid arthritis	0.000112	0.0007	CcSEcCtD
Ponatinib—Nausea—Azathioprine—rheumatoid arthritis	0.000112	0.0007	CcSEcCtD
Ponatinib—Headache—Leflunomide—rheumatoid arthritis	0.000112	0.000697	CcSEcCtD
Ponatinib—Skin disorder—Methylprednisolone—rheumatoid arthritis	0.000112	0.000696	CcSEcCtD
Ponatinib—Malnutrition—Prednisone—rheumatoid arthritis	0.000112	0.000696	CcSEcCtD
Ponatinib—Erythema—Prednisone—rheumatoid arthritis	0.000112	0.000696	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Hydrocortisone—rheumatoid arthritis	0.000112	0.000695	CcSEcCtD
Ponatinib—Hyperhidrosis—Triamcinolone—rheumatoid arthritis	0.000112	0.000695	CcSEcCtD
Ponatinib—Hyperhidrosis—Methylprednisolone—rheumatoid arthritis	0.000111	0.000693	CcSEcCtD
Ponatinib—Insomnia—Hydrocortisone—rheumatoid arthritis	0.000111	0.00069	CcSEcCtD
Ponatinib—Hypertension—Betamethasone—rheumatoid arthritis	0.000111	0.00069	CcSEcCtD
Ponatinib—Hypertension—Dexamethasone—rheumatoid arthritis	0.000111	0.00069	CcSEcCtD
Ponatinib—Paraesthesia—Hydrocortisone—rheumatoid arthritis	0.00011	0.000685	CcSEcCtD
Ponatinib—Myalgia—Dexamethasone—rheumatoid arthritis	0.000109	0.00068	CcSEcCtD
Ponatinib—Myalgia—Betamethasone—rheumatoid arthritis	0.000109	0.00068	CcSEcCtD
Ponatinib—Abdominal pain—Cyclosporine—rheumatoid arthritis	0.000109	0.000679	CcSEcCtD
Ponatinib—Body temperature increased—Cyclosporine—rheumatoid arthritis	0.000109	0.000679	CcSEcCtD
Ponatinib—Dyspepsia—Hydrocortisone—rheumatoid arthritis	0.000108	0.000672	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—rheumatoid arthritis	0.000108	0.000671	CcSEcCtD
Ponatinib—Pain—Prednisolone—rheumatoid arthritis	0.000107	0.000668	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—rheumatoid arthritis	0.000107	0.000668	CcSEcCtD
Ponatinib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	0.000107	0.000663	CcSEcCtD
Ponatinib—Nausea—Leflunomide—rheumatoid arthritis	0.000106	0.000661	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	0.000106	0.000659	CcSEcCtD
Ponatinib—Fatigue—Hydrocortisone—rheumatoid arthritis	0.000106	0.000658	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—rheumatoid arthritis	0.000105	0.000656	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Triamcinolone—rheumatoid arthritis	0.000105	0.000655	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methylprednisolone—rheumatoid arthritis	0.000105	0.000653	CcSEcCtD
Ponatinib—Pain—Hydrocortisone—rheumatoid arthritis	0.000105	0.000653	CcSEcCtD
Ponatinib—Oedema—Betamethasone—rheumatoid arthritis	0.000105	0.000652	CcSEcCtD
Ponatinib—Oedema—Dexamethasone—rheumatoid arthritis	0.000105	0.000652	CcSEcCtD
Ponatinib—Insomnia—Triamcinolone—rheumatoid arthritis	0.000104	0.00065	CcSEcCtD
Ponatinib—Insomnia—Methylprednisolone—rheumatoid arthritis	0.000104	0.000648	CcSEcCtD
Ponatinib—Infection—Betamethasone—rheumatoid arthritis	0.000104	0.000648	CcSEcCtD
Ponatinib—Infection—Dexamethasone—rheumatoid arthritis	0.000104	0.000648	CcSEcCtD
Ponatinib—Paraesthesia—Triamcinolone—rheumatoid arthritis	0.000104	0.000645	CcSEcCtD
Ponatinib—Paraesthesia—Methylprednisolone—rheumatoid arthritis	0.000103	0.000644	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—rheumatoid arthritis	0.000103	0.000644	CcSEcCtD
Ponatinib—Anaemia—Prednisone—rheumatoid arthritis	0.000103	0.000643	CcSEcCtD
Ponatinib—Dyspnoea—Triamcinolone—rheumatoid arthritis	0.000103	0.000641	CcSEcCtD
Ponatinib—Nervous system disorder—Betamethasone—rheumatoid arthritis	0.000103	0.000639	CcSEcCtD
Ponatinib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	0.000103	0.000639	CcSEcCtD
Ponatinib—Thrombocytopenia—Dexamethasone—rheumatoid arthritis	0.000103	0.000638	CcSEcCtD
Ponatinib—Thrombocytopenia—Betamethasone—rheumatoid arthritis	0.000103	0.000638	CcSEcCtD
Ponatinib—Dyspepsia—Triamcinolone—rheumatoid arthritis	0.000102	0.000632	CcSEcCtD
Ponatinib—Dyspepsia—Methylprednisolone—rheumatoid arthritis	0.000101	0.000631	CcSEcCtD
Ponatinib—Hyperhidrosis—Dexamethasone—rheumatoid arthritis	0.000101	0.00063	CcSEcCtD
Ponatinib—Hyperhidrosis—Betamethasone—rheumatoid arthritis	0.000101	0.00063	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—rheumatoid arthritis	0.0001	0.000624	CcSEcCtD
Ponatinib—Gastrointestinal pain—Hydrocortisone—rheumatoid arthritis	0.0001	0.000624	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—rheumatoid arthritis	9.96e-05	0.00062	CcSEcCtD
Ponatinib—Fatigue—Triamcinolone—rheumatoid arthritis	9.95e-05	0.000619	CcSEcCtD
Ponatinib—Fatigue—Methylprednisolone—rheumatoid arthritis	9.93e-05	0.000618	CcSEcCtD
Ponatinib—Asthenia—Cyclosporine—rheumatoid arthritis	9.9e-05	0.000616	CcSEcCtD
Ponatinib—Pain—Triamcinolone—rheumatoid arthritis	9.87e-05	0.000614	CcSEcCtD
Ponatinib—Pruritus—Cyclosporine—rheumatoid arthritis	9.76e-05	0.000607	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—rheumatoid arthritis	9.74e-05	0.000606	CcSEcCtD
Ponatinib—Abdominal pain—Hydrocortisone—rheumatoid arthritis	9.69e-05	0.000603	CcSEcCtD
Ponatinib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	9.69e-05	0.000603	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	9.67e-05	0.000602	CcSEcCtD
Ponatinib—Hypertension—Prednisone—rheumatoid arthritis	9.65e-05	0.000601	CcSEcCtD
Ponatinib—Chills—Methotrexate—rheumatoid arthritis	9.63e-05	0.000599	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Betamethasone—rheumatoid arthritis	9.54e-05	0.000594	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dexamethasone—rheumatoid arthritis	9.54e-05	0.000594	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—rheumatoid arthritis	9.52e-05	0.000592	CcSEcCtD
Ponatinib—Myalgia—Prednisone—rheumatoid arthritis	9.52e-05	0.000592	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—rheumatoid arthritis	9.48e-05	0.00059	CcSEcCtD
Ponatinib—Insomnia—Dexamethasone—rheumatoid arthritis	9.47e-05	0.00059	CcSEcCtD
Ponatinib—Insomnia—Betamethasone—rheumatoid arthritis	9.47e-05	0.00059	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	9.45e-05	0.000588	CcSEcCtD
Ponatinib—Diarrhoea—Cyclosporine—rheumatoid arthritis	9.44e-05	0.000587	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methylprednisolone—rheumatoid arthritis	9.42e-05	0.000586	CcSEcCtD
Ponatinib—Paraesthesia—Dexamethasone—rheumatoid arthritis	9.41e-05	0.000585	CcSEcCtD
Ponatinib—Paraesthesia—Betamethasone—rheumatoid arthritis	9.41e-05	0.000585	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—rheumatoid arthritis	9.4e-05	0.000585	CcSEcCtD
Ponatinib—Erythema—Methotrexate—rheumatoid arthritis	9.34e-05	0.000581	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—rheumatoid arthritis	9.34e-05	0.000581	CcSEcCtD
Ponatinib—Dyspepsia—Dexamethasone—rheumatoid arthritis	9.22e-05	0.000574	CcSEcCtD
Ponatinib—Dyspepsia—Betamethasone—rheumatoid arthritis	9.22e-05	0.000574	CcSEcCtD
Ponatinib—Body temperature increased—Triamcinolone—rheumatoid arthritis	9.13e-05	0.000568	CcSEcCtD
Ponatinib—Dizziness—Cyclosporine—rheumatoid arthritis	9.12e-05	0.000568	CcSEcCtD
Ponatinib—Oedema—Prednisone—rheumatoid arthritis	9.12e-05	0.000568	CcSEcCtD
Ponatinib—Abdominal pain—Methylprednisolone—rheumatoid arthritis	9.11e-05	0.000567	CcSEcCtD
Ponatinib—Decreased appetite—Betamethasone—rheumatoid arthritis	9.11e-05	0.000567	CcSEcCtD
Ponatinib—Decreased appetite—Dexamethasone—rheumatoid arthritis	9.11e-05	0.000567	CcSEcCtD
Ponatinib—Infection—Prednisone—rheumatoid arthritis	9.06e-05	0.000564	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	9.04e-05	0.000563	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	9.04e-05	0.000563	CcSEcCtD
Ponatinib—Back pain—Methotrexate—rheumatoid arthritis	9.04e-05	0.000562	CcSEcCtD
Ponatinib—Fatigue—Dexamethasone—rheumatoid arthritis	9.03e-05	0.000562	CcSEcCtD
Ponatinib—Fatigue—Betamethasone—rheumatoid arthritis	9.03e-05	0.000562	CcSEcCtD
Ponatinib—Pain—Betamethasone—rheumatoid arthritis	8.96e-05	0.000557	CcSEcCtD
Ponatinib—Pain—Dexamethasone—rheumatoid arthritis	8.96e-05	0.000557	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—rheumatoid arthritis	8.95e-05	0.000557	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—rheumatoid arthritis	8.86e-05	0.000551	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—rheumatoid arthritis	8.82e-05	0.000549	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—rheumatoid arthritis	8.8e-05	0.000548	CcSEcCtD
Ponatinib—Asthenia—Hydrocortisone—rheumatoid arthritis	8.8e-05	0.000547	CcSEcCtD
Ponatinib—Vomiting—Cyclosporine—rheumatoid arthritis	8.77e-05	0.000546	CcSEcCtD
Ponatinib—Rash—Cyclosporine—rheumatoid arthritis	8.7e-05	0.000541	CcSEcCtD
Ponatinib—Dermatitis—Cyclosporine—rheumatoid arthritis	8.69e-05	0.000541	CcSEcCtD
Ponatinib—Pruritus—Hydrocortisone—rheumatoid arthritis	8.67e-05	0.00054	CcSEcCtD
Ponatinib—Headache—Cyclosporine—rheumatoid arthritis	8.64e-05	0.000538	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—rheumatoid arthritis	8.63e-05	0.000537	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dexamethasone—rheumatoid arthritis	8.57e-05	0.000533	CcSEcCtD
Ponatinib—Gastrointestinal pain—Betamethasone—rheumatoid arthritis	8.57e-05	0.000533	CcSEcCtD
Ponatinib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	8.39e-05	0.000522	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—rheumatoid arthritis	8.36e-05	0.00052	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—rheumatoid arthritis	8.31e-05	0.000517	CcSEcCtD
Ponatinib—Dizziness—Prednisolone—rheumatoid arthritis	8.3e-05	0.000517	CcSEcCtD
Ponatinib—Asthenia—Triamcinolone—rheumatoid arthritis	8.28e-05	0.000515	CcSEcCtD
Ponatinib—Abdominal pain—Dexamethasone—rheumatoid arthritis	8.28e-05	0.000515	CcSEcCtD
Ponatinib—Abdominal pain—Betamethasone—rheumatoid arthritis	8.28e-05	0.000515	CcSEcCtD
Ponatinib—Body temperature increased—Dexamethasone—rheumatoid arthritis	8.28e-05	0.000515	CcSEcCtD
Ponatinib—Body temperature increased—Betamethasone—rheumatoid arthritis	8.28e-05	0.000515	CcSEcCtD
Ponatinib—Asthenia—Methylprednisolone—rheumatoid arthritis	8.26e-05	0.000514	CcSEcCtD
Ponatinib—Insomnia—Prednisone—rheumatoid arthritis	8.25e-05	0.000513	CcSEcCtD
Ponatinib—Nausea—Cyclosporine—rheumatoid arthritis	8.19e-05	0.00051	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—rheumatoid arthritis	8.19e-05	0.00051	CcSEcCtD
Ponatinib—Pruritus—Triamcinolone—rheumatoid arthritis	8.17e-05	0.000508	CcSEcCtD
Ponatinib—Cough—Methotrexate—rheumatoid arthritis	8.15e-05	0.000507	CcSEcCtD
Ponatinib—Pruritus—Methylprednisolone—rheumatoid arthritis	8.15e-05	0.000507	CcSEcCtD
Ponatinib—Dizziness—Hydrocortisone—rheumatoid arthritis	8.11e-05	0.000505	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—rheumatoid arthritis	8.03e-05	0.0005	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—rheumatoid arthritis	7.95e-05	0.000495	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—rheumatoid arthritis	7.95e-05	0.000495	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—rheumatoid arthritis	7.93e-05	0.000494	CcSEcCtD
Ponatinib—Rash—Prednisolone—rheumatoid arthritis	7.92e-05	0.000493	CcSEcCtD
Ponatinib—Dermatitis—Prednisolone—rheumatoid arthritis	7.91e-05	0.000492	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	7.9e-05	0.000492	CcSEcCtD
Ponatinib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	7.88e-05	0.000491	CcSEcCtD
Ponatinib—Fatigue—Prednisone—rheumatoid arthritis	7.87e-05	0.000489	CcSEcCtD
Ponatinib—Headache—Prednisolone—rheumatoid arthritis	7.86e-05	0.000489	CcSEcCtD
Ponatinib—Constipation—Prednisone—rheumatoid arthritis	7.8e-05	0.000486	CcSEcCtD
Ponatinib—Vomiting—Hydrocortisone—rheumatoid arthritis	7.8e-05	0.000485	CcSEcCtD
Ponatinib—Rash—Hydrocortisone—rheumatoid arthritis	7.73e-05	0.000481	CcSEcCtD
Ponatinib—Dermatitis—Hydrocortisone—rheumatoid arthritis	7.72e-05	0.000481	CcSEcCtD
Ponatinib—Headache—Hydrocortisone—rheumatoid arthritis	7.68e-05	0.000478	CcSEcCtD
Ponatinib—Dizziness—Triamcinolone—rheumatoid arthritis	7.63e-05	0.000475	CcSEcCtD
Ponatinib—Dizziness—Methylprednisolone—rheumatoid arthritis	7.62e-05	0.000474	CcSEcCtD
Ponatinib—Infection—Methotrexate—rheumatoid arthritis	7.57e-05	0.000471	CcSEcCtD
Ponatinib—Asthenia—Dexamethasone—rheumatoid arthritis	7.52e-05	0.000468	CcSEcCtD
Ponatinib—Asthenia—Betamethasone—rheumatoid arthritis	7.52e-05	0.000468	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—rheumatoid arthritis	7.48e-05	0.000465	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—rheumatoid arthritis	7.46e-05	0.000465	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—rheumatoid arthritis	7.46e-05	0.000464	CcSEcCtD
Ponatinib—Nausea—Prednisolone—rheumatoid arthritis	7.46e-05	0.000464	CcSEcCtD
Ponatinib—Pruritus—Dexamethasone—rheumatoid arthritis	7.41e-05	0.000461	CcSEcCtD
Ponatinib—Pruritus—Betamethasone—rheumatoid arthritis	7.41e-05	0.000461	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—rheumatoid arthritis	7.41e-05	0.000461	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—rheumatoid arthritis	7.37e-05	0.000459	CcSEcCtD
Ponatinib—Vomiting—Triamcinolone—rheumatoid arthritis	7.34e-05	0.000457	CcSEcCtD
Ponatinib—Vomiting—Methylprednisolone—rheumatoid arthritis	7.32e-05	0.000456	CcSEcCtD
Ponatinib—Nausea—Hydrocortisone—rheumatoid arthritis	7.28e-05	0.000453	CcSEcCtD
Ponatinib—Rash—Triamcinolone—rheumatoid arthritis	7.28e-05	0.000453	CcSEcCtD
Ponatinib—Dermatitis—Triamcinolone—rheumatoid arthritis	7.27e-05	0.000453	CcSEcCtD
Ponatinib—Rash—Methylprednisolone—rheumatoid arthritis	7.26e-05	0.000452	CcSEcCtD
Ponatinib—Dermatitis—Methylprednisolone—rheumatoid arthritis	7.26e-05	0.000452	CcSEcCtD
Ponatinib—Headache—Triamcinolone—rheumatoid arthritis	7.23e-05	0.00045	CcSEcCtD
Ponatinib—Headache—Methylprednisolone—rheumatoid arthritis	7.22e-05	0.000449	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—rheumatoid arthritis	7.21e-05	0.000449	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—rheumatoid arthritis	7.21e-05	0.000449	CcSEcCtD
Ponatinib—Diarrhoea—Dexamethasone—rheumatoid arthritis	7.17e-05	0.000446	CcSEcCtD
Ponatinib—Diarrhoea—Betamethasone—rheumatoid arthritis	7.17e-05	0.000446	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—rheumatoid arthritis	6.95e-05	0.000432	CcSEcCtD
Ponatinib—Dizziness—Dexamethasone—rheumatoid arthritis	6.93e-05	0.000431	CcSEcCtD
Ponatinib—Dizziness—Betamethasone—rheumatoid arthritis	6.93e-05	0.000431	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—rheumatoid arthritis	6.9e-05	0.000429	CcSEcCtD
Ponatinib—Nausea—Triamcinolone—rheumatoid arthritis	6.86e-05	0.000427	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—rheumatoid arthritis	6.85e-05	0.000426	CcSEcCtD
Ponatinib—Nausea—Methylprednisolone—rheumatoid arthritis	6.84e-05	0.000426	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—rheumatoid arthritis	6.8e-05	0.000423	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—rheumatoid arthritis	6.71e-05	0.000418	CcSEcCtD
Ponatinib—Vomiting—Dexamethasone—rheumatoid arthritis	6.66e-05	0.000415	CcSEcCtD
Ponatinib—Vomiting—Betamethasone—rheumatoid arthritis	6.66e-05	0.000415	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—rheumatoid arthritis	6.63e-05	0.000412	CcSEcCtD
Ponatinib—Rash—Dexamethasone—rheumatoid arthritis	6.6e-05	0.000411	CcSEcCtD
Ponatinib—Rash—Betamethasone—rheumatoid arthritis	6.6e-05	0.000411	CcSEcCtD
Ponatinib—Dermatitis—Dexamethasone—rheumatoid arthritis	6.6e-05	0.000411	CcSEcCtD
Ponatinib—Dermatitis—Betamethasone—rheumatoid arthritis	6.6e-05	0.000411	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	6.58e-05	0.00041	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—rheumatoid arthritis	6.57e-05	0.000409	CcSEcCtD
Ponatinib—Headache—Betamethasone—rheumatoid arthritis	6.56e-05	0.000408	CcSEcCtD
Ponatinib—Headache—Dexamethasone—rheumatoid arthritis	6.56e-05	0.000408	CcSEcCtD
Ponatinib—Asthenia—Prednisone—rheumatoid arthritis	6.55e-05	0.000407	CcSEcCtD
Ponatinib—Pain—Methotrexate—rheumatoid arthritis	6.52e-05	0.000406	CcSEcCtD
Ponatinib—Pruritus—Prednisone—rheumatoid arthritis	6.45e-05	0.000402	CcSEcCtD
Ponatinib—Diarrhoea—Prednisone—rheumatoid arthritis	6.24e-05	0.000388	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—rheumatoid arthritis	6.23e-05	0.000388	CcSEcCtD
Ponatinib—Nausea—Dexamethasone—rheumatoid arthritis	6.22e-05	0.000387	CcSEcCtD
Ponatinib—Nausea—Betamethasone—rheumatoid arthritis	6.22e-05	0.000387	CcSEcCtD
Ponatinib—Dizziness—Prednisone—rheumatoid arthritis	6.03e-05	0.000375	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—rheumatoid arthritis	6.03e-05	0.000375	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—rheumatoid arthritis	6.03e-05	0.000375	CcSEcCtD
Ponatinib—Vomiting—Prednisone—rheumatoid arthritis	5.8e-05	0.000361	CcSEcCtD
Ponatinib—Rash—Prednisone—rheumatoid arthritis	5.75e-05	0.000358	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—rheumatoid arthritis	5.75e-05	0.000358	CcSEcCtD
Ponatinib—Headache—Prednisone—rheumatoid arthritis	5.72e-05	0.000356	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—rheumatoid arthritis	5.47e-05	0.00034	CcSEcCtD
Ponatinib—Nausea—Prednisone—rheumatoid arthritis	5.42e-05	0.000337	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—rheumatoid arthritis	5.39e-05	0.000336	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—rheumatoid arthritis	5.22e-05	0.000325	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—rheumatoid arthritis	5.04e-05	0.000314	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—rheumatoid arthritis	4.85e-05	0.000302	CcSEcCtD
Ponatinib—Rash—Methotrexate—rheumatoid arthritis	4.81e-05	0.000299	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—rheumatoid arthritis	4.8e-05	0.000299	CcSEcCtD
Ponatinib—Headache—Methotrexate—rheumatoid arthritis	4.78e-05	0.000297	CcSEcCtD
Ponatinib—Nausea—Methotrexate—rheumatoid arthritis	4.53e-05	0.000282	CcSEcCtD
Ponatinib—PDGFRA—Signaling Pathways—CD80—rheumatoid arthritis	3.68e-06	1.48e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—rheumatoid arthritis	3.67e-06	1.48e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6R—rheumatoid arthritis	3.67e-06	1.47e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MTHFR—rheumatoid arthritis	3.66e-06	1.47e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTK2—rheumatoid arthritis	3.66e-06	1.47e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD80—rheumatoid arthritis	3.64e-06	1.46e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—rheumatoid arthritis	3.62e-06	1.46e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCL2—rheumatoid arthritis	3.61e-06	1.45e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6R—rheumatoid arthritis	3.6e-06	1.45e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL5—rheumatoid arthritis	3.59e-06	1.44e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—LEP—rheumatoid arthritis	3.59e-06	1.44e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—rheumatoid arthritis	3.56e-06	1.43e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—rheumatoid arthritis	3.54e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—rheumatoid arthritis	3.54e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1B—rheumatoid arthritis	3.54e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CSF2—rheumatoid arthritis	3.53e-06	1.42e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—rheumatoid arthritis	3.53e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—rheumatoid arthritis	3.52e-06	1.42e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1B—rheumatoid arthritis	3.52e-06	1.42e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—rheumatoid arthritis	3.52e-06	1.41e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6R—rheumatoid arthritis	3.52e-06	1.41e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—rheumatoid arthritis	3.51e-06	1.41e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—rheumatoid arthritis	3.51e-06	1.41e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—POMC—rheumatoid arthritis	3.5e-06	1.41e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—POMC—rheumatoid arthritis	3.49e-06	1.4e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6ST—rheumatoid arthritis	3.49e-06	1.4e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—TYK2—rheumatoid arthritis	3.47e-06	1.4e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS2—rheumatoid arthritis	3.46e-06	1.39e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—rheumatoid arthritis	3.43e-06	1.38e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL2—rheumatoid arthritis	3.43e-06	1.38e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL2—rheumatoid arthritis	3.42e-06	1.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6R—rheumatoid arthritis	3.42e-06	1.37e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6R—rheumatoid arthritis	3.41e-06	1.37e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—rheumatoid arthritis	3.39e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FN1—rheumatoid arthritis	3.38e-06	1.36e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6R—rheumatoid arthritis	3.37e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6ST—rheumatoid arthritis	3.37e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP3—rheumatoid arthritis	3.36e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD80—rheumatoid arthritis	3.36e-06	1.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TYK2—rheumatoid arthritis	3.34e-06	1.34e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—rheumatoid arthritis	3.33e-06	1.34e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SPP1—rheumatoid arthritis	3.32e-06	1.34e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NFKB1—rheumatoid arthritis	3.3e-06	1.33e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NFKB1—rheumatoid arthritis	3.29e-06	1.32e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO1—rheumatoid arthritis	3.29e-06	1.32e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NFKB1—rheumatoid arthritis	3.28e-06	1.32e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TYK2—rheumatoid arthritis	3.28e-06	1.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NOS3—rheumatoid arthritis	3.28e-06	1.32e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	3.25e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IFNG—rheumatoid arthritis	3.25e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK8—rheumatoid arthritis	3.24e-06	1.3e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CD80—rheumatoid arthritis	3.24e-06	1.3e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK8—rheumatoid arthritis	3.24e-06	1.3e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTK2—rheumatoid arthritis	3.24e-06	1.3e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR5—rheumatoid arthritis	3.23e-06	1.3e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MED1—rheumatoid arthritis	3.23e-06	1.3e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK8—rheumatoid arthritis	3.23e-06	1.3e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NOS3—rheumatoid arthritis	3.22e-06	1.29e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—rheumatoid arthritis	3.21e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TYK2—rheumatoid arthritis	3.2e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2RA—rheumatoid arthritis	3.18e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL5—rheumatoid arthritis	3.18e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—C3—rheumatoid arthritis	3.16e-06	1.27e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TGFB1—rheumatoid arthritis	3.15e-06	1.27e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NOS3—rheumatoid arthritis	3.15e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAT—rheumatoid arthritis	3.14e-06	1.26e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD4—rheumatoid arthritis	3.14e-06	1.26e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—rheumatoid arthritis	3.13e-06	1.26e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CSF2—rheumatoid arthritis	3.13e-06	1.26e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6R—rheumatoid arthritis	3.11e-06	1.25e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TYK2—rheumatoid arthritis	3.11e-06	1.25e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TYK2—rheumatoid arthritis	3.1e-06	1.25e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO1—rheumatoid arthritis	3.1e-06	1.25e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—TGFB1—rheumatoid arthritis	3.09e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—POMC—rheumatoid arthritis	3.08e-06	1.24e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	3.08e-06	1.24e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—TYK2—rheumatoid arthritis	3.07e-06	1.24e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NOS3—rheumatoid arthritis	3.05e-06	1.23e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NOS3—rheumatoid arthritis	3.05e-06	1.23e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—TGFB1—rheumatoid arthritis	3.04e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL2—rheumatoid arthritis	3.01e-06	1.21e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6R—rheumatoid arthritis	3.01e-06	1.21e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	3e-06	1.21e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	3e-06	1.21e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—rheumatoid arthritis	2.99e-06	1.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SPP1—rheumatoid arthritis	2.94e-06	1.18e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—LEP—rheumatoid arthritis	2.94e-06	1.18e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—POMC—rheumatoid arthritis	2.93e-06	1.18e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—rheumatoid arthritis	2.92e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—rheumatoid arthritis	2.91e-06	1.17e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL8—rheumatoid arthritis	2.91e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—rheumatoid arthritis	2.9e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CD4—rheumatoid arthritis	2.9e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—rheumatoid arthritis	2.89e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TGFB1—rheumatoid arthritis	2.88e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IFNG—rheumatoid arthritis	2.88e-06	1.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TGFB1—rheumatoid arthritis	2.88e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—rheumatoid arthritis	2.88e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR5—rheumatoid arthritis	2.86e-06	1.15e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL8—rheumatoid arthritis	2.85e-06	1.15e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TYK2—rheumatoid arthritis	2.84e-06	1.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2RA—rheumatoid arthritis	2.82e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—C3—rheumatoid arthritis	2.8e-06	1.12e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS3—rheumatoid arthritis	2.78e-06	1.12e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—rheumatoid arthritis	2.78e-06	1.12e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—rheumatoid arthritis	2.78e-06	1.12e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FN1—rheumatoid arthritis	2.77e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6ST—rheumatoid arthritis	2.76e-06	1.11e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TGFB1—rheumatoid arthritis	2.74e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TYK2—rheumatoid arthritis	2.74e-06	1.1e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—rheumatoid arthritis	2.73e-06	1.1e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAT—rheumatoid arthritis	2.72e-06	1.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL8—rheumatoid arthritis	2.71e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NFKB1—rheumatoid arthritis	2.7e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	2.7e-06	1.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL8—rheumatoid arthritis	2.7e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NOS3—rheumatoid arthritis	2.69e-06	1.08e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ALB—rheumatoid arthritis	2.67e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK8—rheumatoid arthritis	2.66e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CD80—rheumatoid arthritis	2.66e-06	1.07e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—rheumatoid arthritis	2.63e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—rheumatoid arthritis	2.62e-06	1.05e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—LEP—rheumatoid arthritis	2.6e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NFKB1—rheumatoid arthritis	2.6e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—rheumatoid arthritis	2.59e-06	1.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—rheumatoid arthritis	2.59e-06	1.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—rheumatoid arthritis	2.58e-06	1.04e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—rheumatoid arthritis	2.58e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—rheumatoid arthritis	2.58e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—rheumatoid arthritis	2.57e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—rheumatoid arthritis	2.57e-06	1.03e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK8—rheumatoid arthritis	2.56e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—rheumatoid arthritis	2.56e-06	1.03e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NFKB1—rheumatoid arthritis	2.55e-06	1.03e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NOS3—rheumatoid arthritis	2.55e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—rheumatoid arthritis	2.55e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—rheumatoid arthritis	2.53e-06	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—rheumatoid arthritis	2.53e-06	1.02e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK8—rheumatoid arthritis	2.51e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	2.49e-06	1e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—rheumatoid arthritis	2.48e-06	9.97e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—rheumatoid arthritis	2.47e-06	9.94e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6R—rheumatoid arthritis	2.46e-06	9.91e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FN1—rheumatoid arthritis	2.45e-06	9.87e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—rheumatoid arthritis	2.45e-06	9.85e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6ST—rheumatoid arthritis	2.44e-06	9.83e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—rheumatoid arthritis	2.44e-06	9.83e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NFKB1—rheumatoid arthritis	2.42e-06	9.75e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NFKB1—rheumatoid arthritis	2.42e-06	9.72e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—NFKB1—rheumatoid arthritis	2.39e-06	9.63e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—rheumatoid arthritis	2.38e-06	9.59e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK8—rheumatoid arthritis	2.38e-06	9.58e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK8—rheumatoid arthritis	2.38e-06	9.56e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—rheumatoid arthritis	2.37e-06	9.55e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAT—rheumatoid arthritis	2.37e-06	9.53e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—rheumatoid arthritis	2.36e-06	9.49e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—rheumatoid arthritis	2.35e-06	9.47e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK8—rheumatoid arthritis	2.35e-06	9.46e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CD80—rheumatoid arthritis	2.35e-06	9.46e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—rheumatoid arthritis	2.35e-06	9.44e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—rheumatoid arthritis	2.33e-06	9.39e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—rheumatoid arthritis	2.33e-06	9.38e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—rheumatoid arthritis	2.32e-06	9.32e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—rheumatoid arthritis	2.29e-06	9.21e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—rheumatoid arthritis	2.28e-06	9.16e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—rheumatoid arthritis	2.27e-06	9.13e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—rheumatoid arthritis	2.26e-06	9.09e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TYK2—rheumatoid arthritis	2.24e-06	9.02e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—rheumatoid arthritis	2.24e-06	8.99e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAT—rheumatoid arthritis	2.23e-06	8.98e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—rheumatoid arthritis	2.2e-06	8.86e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—rheumatoid arthritis	2.2e-06	8.85e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—rheumatoid arthritis	2.19e-06	8.83e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—rheumatoid arthritis	2.19e-06	8.8e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6R—rheumatoid arthritis	2.18e-06	8.77e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—rheumatoid arthritis	2.17e-06	8.74e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—rheumatoid arthritis	2.17e-06	8.72e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—rheumatoid arthritis	2.17e-06	8.71e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—rheumatoid arthritis	2.16e-06	8.67e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKB1—rheumatoid arthritis	2.13e-06	8.58e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—rheumatoid arthritis	2.13e-06	8.56e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—rheumatoid arthritis	2.1e-06	8.43e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—rheumatoid arthritis	2.1e-06	8.43e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—rheumatoid arthritis	2.08e-06	8.36e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—rheumatoid arthritis	2.07e-06	8.33e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—rheumatoid arthritis	2.07e-06	8.32e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—rheumatoid arthritis	2.06e-06	8.29e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	2.03e-06	8.16e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—rheumatoid arthritis	2.02e-06	8.12e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—rheumatoid arthritis	2.01e-06	8.1e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TYK2—rheumatoid arthritis	1.99e-06	7.99e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—rheumatoid arthritis	1.98e-06	7.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—rheumatoid arthritis	1.95e-06	7.86e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—rheumatoid arthritis	1.95e-06	7.84e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—rheumatoid arthritis	1.94e-06	7.78e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—rheumatoid arthritis	1.91e-06	7.69e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—rheumatoid arthritis	1.87e-06	7.51e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—rheumatoid arthritis	1.86e-06	7.5e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—rheumatoid arthritis	1.84e-06	7.4e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—rheumatoid arthritis	1.83e-06	7.35e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—rheumatoid arthritis	1.82e-06	7.3e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—rheumatoid arthritis	1.78e-06	7.17e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—rheumatoid arthritis	1.78e-06	7.15e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—rheumatoid arthritis	1.77e-06	7.11e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—rheumatoid arthritis	1.75e-06	7.05e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKB1—rheumatoid arthritis	1.75e-06	7.03e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—rheumatoid arthritis	1.73e-06	6.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—rheumatoid arthritis	1.72e-06	6.91e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—rheumatoid arthritis	1.7e-06	6.83e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—rheumatoid arthritis	1.67e-06	6.72e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—rheumatoid arthritis	1.66e-06	6.69e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—rheumatoid arthritis	1.66e-06	6.67e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—rheumatoid arthritis	1.66e-06	6.66e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—rheumatoid arthritis	1.65e-06	6.65e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—rheumatoid arthritis	1.63e-06	6.57e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—rheumatoid arthritis	1.6e-06	6.45e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—rheumatoid arthritis	1.59e-06	6.38e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—rheumatoid arthritis	1.58e-06	6.37e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—rheumatoid arthritis	1.58e-06	6.36e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—rheumatoid arthritis	1.57e-06	6.3e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—rheumatoid arthritis	1.56e-06	6.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKB1—rheumatoid arthritis	1.55e-06	6.22e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—rheumatoid arthritis	1.52e-06	6.12e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—rheumatoid arthritis	1.52e-06	6.12e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—rheumatoid arthritis	1.52e-06	6.1e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—rheumatoid arthritis	1.5e-06	6.04e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—rheumatoid arthritis	1.49e-06	5.99e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—rheumatoid arthritis	1.46e-06	5.88e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	1.46e-06	5.87e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—rheumatoid arthritis	1.46e-06	5.86e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—rheumatoid arthritis	1.45e-06	5.82e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—rheumatoid arthritis	1.44e-06	5.8e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—rheumatoid arthritis	1.4e-06	5.65e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—rheumatoid arthritis	1.39e-06	5.58e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—rheumatoid arthritis	1.38e-06	5.55e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—rheumatoid arthritis	1.36e-06	5.47e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—rheumatoid arthritis	1.34e-06	5.38e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—rheumatoid arthritis	1.3e-06	5.23e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—rheumatoid arthritis	1.29e-06	5.18e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—rheumatoid arthritis	1.26e-06	5.07e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	1.22e-06	4.9e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—rheumatoid arthritis	1.2e-06	4.82e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—rheumatoid arthritis	1.19e-06	4.78e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—rheumatoid arthritis	1.1e-06	4.41e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—rheumatoid arthritis	1.06e-06	4.27e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	9.75e-07	3.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—rheumatoid arthritis	9.72e-07	3.91e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	8.89e-07	3.57e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	8.5e-07	3.42e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	7.77e-07	3.13e-06	CbGpPWpGaD
